Skip to Main Content
Services Talent Knowledge
Site Search
Menu

PressRelease

January 20, 2009

Hiscock & Barclay Partner Robert Barrer Elected to American Board of Trial Advocate

Hiscock & Barclay, LLP Partner Robert A. Barrer has been elected into the membership of the American Board of Trial Advocates (ABOTA). ABOTA is an invitation-only national organization of the finest trial lawyers and judges in America who have substantial civil jury trial experience, possess additional litigation experience and exhibit the virtues of civility, integrity and professionalism.

Barrer concentrates his practice in complex commercial and tort litigation. He has extensive trial and appellate experience in state and federal cases involving commercial law, products liability and toxic torts, insurance coverage and labor and employment. He is Hiscock & Barclay's Chief Ethics Officer and also serves as the Continuing Legal Education Coordinator and liaison with the New York State Continuing Legal Education Board.

Founded in 1958, ABOTA and its members are dedicated to the preservation and promotion of the civil jury trial right provided by the 7th Amendment to the U.S. Constitution.

Subscribe

Click here to sign up for alerts, blog posts, and firm news.

Featured Media

Alerts

Website Accessibility Lawsuits: Several "Tester" Plaintiffs—Nathalie Reyes, Aisha Raheel, Simon Isakov, Amanie Riley, and Victor Andrews—Targeting Businesses in Recent Flurry of Lawsuits

Alerts

Website Accessibility Lawsuits: Several "Tester" Plaintiffs—Sandra Ford, Z'Leah Liburd, Livingston Bennett, Brandi Major, and Joshua Espinal—Targeting Businesses in Recent Flurry of Lawsuits

Alerts

Year-End Focus for 403(b) Plan Sponsors: Two Critical Document Deadlines and Typical Year-End Compliance Review

Alerts

Second Circuit Reverses Award of Attorney's Fees in Coverage Dispute Between Liability Insurers

Alerts

Federal Court Narrows Scope of Insurers' Privilege Claims in COVID-19 Coverage Litigation

Alerts

AstraZeneca Escalates FARXIGA® Audit Demands: What Pharmacies Need to Know Now